Drug intelligence / Profile preview

CLXR-001

Development stage: Unknown
Lead developer: Cardiogeni
Modality: Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

CLXR-001 is an investigational cell therapy developed by Cardiogeni, consisting of Ischemic Myocardial Progenitor (iMP) cells. These cells are specifically defined by the expression of surface markers including CD304 (Neuropilin-1), EGFR, CD363 (S1PR1), and IL-8R. CLXR-001 is designed to treat heart failure and ischemic cardiomyopathy by promoting myocardial repair, stimulating angiogenesis, and improving cardiac function through the regenerative potential of the progenitor cells. The therapy is currently in Phase 2 clinical development, targeting patients with chronic heart failure resulting from ischemic injury.

Other names: iMP cell therapyIschemic Myocardial Progenitor cell therapy

Beyond the preview

Go deeper on CLXR-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLXR-001.

Explore the full profile